Kommersiellt obunden läkemedelsinformation riktad till läkare och sjukvårdspersonal

Drospirenon

Classification: B

Drug products: Angemin®, Cleodette, Cleodette 28, Cleonita, Cleosensa, Cleosensa 28, Daylette, Diza, Dizmine 28, Dizminelle, Eloine, Estrelen, Estron, Liofora, Midiana, Midiana 28, Rosal 28, Stefaminelle, Yasmin®, Yasmin® 28, Yasminelle, Yasminelle 28, Yaz, Zelle, Zellmine, Zellmine 28, Zellminelle, Zellminelle 28

ATC code: G03AA12, G03FA17

Substances: drospirenone

Summary

As the substance is only used by women, analyses on sex or gender differences have not been considered relevant.

Additional information

The approved indication for drospirenon in combination with ethinylestradiol is contraception [1,2], substitution of estrogen deficiency in women more than one year after menopause, and prevention of osteoporosis in postmenopausal women at high risk of future fracture with intolerance to, or have contraindications for, other medical drugs approved for the prevention of osteoporosis [2].

Updated: 2016-12-23

Date of litterature search: 2016-12-20

References

  1. Fass.se [cited 2016-12-20]. länk
  2. Physicians' Desk Reference. http://www.pdr.net. [cited 2016-12-20]. länk
  3. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2015 [cited 2016-12-19.] Socialstyrelsens statistikdatabas

Authors: Mia von Euler, Linnéa Karlsson Lind

Reviewed by: Mia von Euler

Approved by: Karin Schenck-Gustafsson